Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report

View Full Paper
Ask AI
Bookmark
Share

Authors

XQXiaoyu QuSJShahanawaz JiwaniHEHarry P. Erba

Discussion

Loading...

Member takes

Overview

Retrospective clinical trial shows CGAT improves diagnostic yield in AML and MDS, indicating enhanced risk stratification.

Key Points

  • CGAT significantly improved diagnostic yield for AML/MDS patients, achieving an increase of approximately 20%.
  • In 11.4% of cases, CGAT altered risk stratification based on ELN criteria, highlighting its clinical utility.
  • Clinical trial findings underscore the importance of CGAT in detecting unique abnormalities, including complex genome configurations.
  • Routine incorporation of CGAT for intermediate risk AML/MDS patients could enhance precision medicine efforts.

Cite This Study

Qu et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236d9fbhttps://doi.org/10.1182/blood-2025-3501
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SNP-Based Chromosomal Microarray Analysis in the Era of Optical Genome Mapping: An Enriched Case-Series Evaluating Copy-Neutral Events2026
  2. 2Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia2025
  3. 3Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.2025 · 1 citations
  4. 4Maximizing the potential of optical genome mapping through comprehensive automated data analysis in multiple myeloma2025
  5. 5The Diagnostic Utility of Prenatal Microarray in High-Risk Pregnancies: A Single-Center Experience to Enhance Reproductive Care and Risk Stratification2025